ARTIOS Ofatumumab in relapsingMS patients moving from other therapies
Research type
Research Study
Full title
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy
IRAS ID
275978
Contact name
Jane Watson
Contact email
Sponsor organisation
Novartis Pharma AG
Eudract number
2019-001341-40
Duration of Study in the UK
3 years, 3 months, 4 days
Research summary
The purpose of this study is to evaluate the safety and effectiveness of ofatumumab treatment in patients who are transitioning from their current multiple sclerosis (MS) treatment (DMF or fingolimod) due to breakthrough disease, onto ofatumumab. In addition, the study will explore the utility of biomarkers and digital tools in the assessment and treatment of people living with MS. The study will be run in 8 centred in the UK but only 6 have been selected at the time of submission. The remaining 2 will be submitted once known.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
20/WM/0082
Date of REC Opinion
22 Apr 2020
REC opinion
Further Information Favourable Opinion